Autologous blood-derived hematopoietic progenitors can be used like autologous bone marrow to restore hematopoiesis following marrow ablative therapy. Peripheral stem cell transplantation (PSCT) is preferable to autologous bone marrow transplantation (ABMT) if autologous marrow is not suitable for use as a graft product. Generally, this unsuitability results from marrow hypocellularity or metastatic disease. PSCT also has an advantage over ABMT in that it often restores marrow function more rapidly.
|Original language||English (US)|
|Number of pages||11|
|Journal||Hematology/Oncology Clinics of North America|
|Publication status||Published - Jan 1 1993|
ASJC Scopus subject areas